Cantor Fitzgerald Initiates Coverage On Tvardi Therapeutics with Overweight Rating, Announces Price Target of $52
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Overweight rating and announces Price Target of $52.
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Overweight rating and announces Price Target of $52.